[go: up one dir, main page]

BR9605153A - Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos - Google Patents

Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos

Info

Publication number
BR9605153A
BR9605153A BR9605153A BR9605153A BR9605153A BR 9605153 A BR9605153 A BR 9605153A BR 9605153 A BR9605153 A BR 9605153A BR 9605153 A BR9605153 A BR 9605153A BR 9605153 A BR9605153 A BR 9605153A
Authority
BR
Brazil
Prior art keywords
newcastle disease
chickens
combination vaccine
chickens against
against newcastle
Prior art date
Application number
BR9605153A
Other languages
English (en)
Other versions
BR9605153B1 (pt
Inventor
Heinrich Dieter Lutticken
Carla Christina Schrier
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9605153A publication Critical patent/BR9605153A/pt
Publication of BR9605153B1 publication Critical patent/BR9605153B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI9605153-1A 1995-10-18 1996-10-17 vacina de combinação, e, kit de vacinação. BR9605153B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202810 1995-10-18

Publications (2)

Publication Number Publication Date
BR9605153A true BR9605153A (pt) 1998-07-14
BR9605153B1 BR9605153B1 (pt) 2010-07-27

Family

ID=8220728

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9605153-1A BR9605153B1 (pt) 1995-10-18 1996-10-17 vacina de combinação, e, kit de vacinação.

Country Status (11)

Country Link
US (1) US5733556A (pt)
EP (1) EP0770397B1 (pt)
JP (1) JP3947254B2 (pt)
AT (1) ATE264691T1 (pt)
BR (1) BR9605153B1 (pt)
CA (1) CA2187974C (pt)
DE (1) DE69632235T2 (pt)
DK (1) DK0770397T3 (pt)
ES (1) ES2219679T3 (pt)
MX (1) MX9604907A (pt)
PT (1) PT770397E (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
CA2312626A1 (en) * 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
WO2002078732A1 (en) * 2001-02-15 2002-10-10 The Registrar, Indian Institute Of Science A noval vaccine formulation consisting of dna vaccine inactivated virus
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040146530A1 (en) * 2002-01-30 2004-07-29 Sharma Jagdev M Avian vaccine effective against infectious bursal disease virus
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
CA2500661A1 (en) * 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
ES2524556T3 (es) * 2006-10-09 2014-12-10 Charleston Laboratories, Inc. Composiciones farmacéuticas
BRPI0814409A2 (pt) * 2007-07-06 2014-10-14 Nuon Therapeutics Inc Tratamento de dor neuropática
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US9056857B2 (en) 2008-12-22 2015-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
JP2012513471A (ja) 2008-12-22 2012-06-14 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ アルツハイマー病および癌の治療のためのクマリン系化合物
JP2012518635A (ja) 2009-02-24 2012-08-16 リター ファーマシューティカルズ インコーポレイテッド プレバイオティック製剤および使用方法
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
KR101099629B1 (ko) 2009-10-27 2011-12-29 건국대학교 산학협력단 신규한 뉴캣슬병 바이러스 ｋ148/08주, 및 그 바이러스를 함유하는 뉴캣슬병 백신
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
JP5913316B2 (ja) * 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
JP2015523546A (ja) 2012-05-01 2015-08-13 トランスレイタム メディカス インコーポレイテッド 失明性疾患を処置および診断するための方法
JP6210998B2 (ja) * 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US11021435B2 (en) 2014-05-19 2021-06-01 Northeastern University Serotonin receptor-targeting compounds and methods
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10183060B2 (en) 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3411065B1 (en) 2016-02-05 2021-03-31 Orionis Biosciences BV Clec9a binding agents
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
EP3585410B9 (en) 2017-02-27 2023-10-04 Shattuck Labs, Inc. Vsig8-based chimeric proteins
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 LINKERS AND THEIR USES
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3844175A4 (en) 2018-08-29 2022-08-24 Shattuck Labs, Inc. COMBINATION THERAPIES WITH PD-1-BASED CHIMERIC PROTEINS
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
KR20220056241A (ko) * 2019-09-11 2022-05-04 조에티스 서비시즈 엘엘씨 조류 병원체의 항원을 발현하는 재조합 칠면조 헤르페스바이러스 벡터 및 이의 용도
CN111334464B (zh) * 2020-03-30 2023-05-12 重庆市畜牧科学院 鹅副粘病毒在加快鹅成纤维细胞增殖速度中的应用
CN114164182B (zh) * 2020-09-10 2024-02-06 青岛易邦生物工程有限公司 一种基因vii型遗传拯救的新城疫病毒疫苗株
CN113376387B (zh) * 2021-07-13 2023-03-24 中崇信诺生物科技泰州有限公司 一种鸽新城疫Ⅵb亚型阳性血清标准品及其制备方法
US20230144855A1 (en) 2021-09-01 2023-05-11 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin
US20240424022A1 (en) 2021-09-01 2024-12-26 Flagship Pioneering Innovations Vi, Llc In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
WO2023034508A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for promoting adipocyte beiging
EP4396331A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
EP4399278A1 (en) 2021-09-09 2024-07-17 Flagship Pioneering Innovations VI, LLC Methods and compositions for modulating enteroendocrine cells
WO2023039164A2 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023043827A2 (en) 2021-09-14 2023-03-23 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
EP4436407A1 (en) 2021-11-22 2024-10-02 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
ES2060740T3 (es) * 1988-07-18 1994-12-01 Duphar Int Res Vacunas de virus vivos para la enfermedad de newcastle.
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
HU203983B (en) * 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
US5118502A (en) * 1989-06-20 1992-06-02 The University Of Georgia Research Foundation, Inc. Naturally attenuated newcastle disease vaccine and method of using the same
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal

Also Published As

Publication number Publication date
JPH09169663A (ja) 1997-06-30
MX9604907A (es) 1997-04-30
DE69632235D1 (de) 2004-05-27
DK0770397T3 (da) 2004-08-09
EP0770397B1 (en) 2004-04-21
PT770397E (pt) 2004-08-31
ES2219679T3 (es) 2004-12-01
US5733556A (en) 1998-03-31
JP3947254B2 (ja) 2007-07-18
BR9605153B1 (pt) 2010-07-27
CA2187974C (en) 2006-08-29
CA2187974A1 (en) 1997-04-19
EP0770397A1 (en) 1997-05-02
DE69632235T2 (de) 2004-08-26
ATE264691T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
BR9605153A (pt) Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
ES2152292T3 (es) Vacuna para aves de corral que contiene el virus de la bronquitis infecciosa 4/91.
AU7814498A (en) Multivalent (in ovo) avian vaccine
DK0838222T3 (da) Vaccinesammensætninger, der omfatter inaktiverede immunogener og levende kyllingeanæmi-virus (CAV)
ES2177535T3 (es) Vacunas contra protozoos intestinales.
BR9603227A (pt) Vírus ndv da cepa c2 vacina para uso na proteção de aves omésticas contra doença de newcastle (nd) processos para a preparação de vírus para preparação de uma vacina e para controlar doença de newcastle em aves domésticas
ATE334697T1 (de) Boviner atmungs- und darmcoronavirus als impfstoff
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
AR010794A1 (es) Vacuna para la vacunacion in ovo de aves de corral contra la enfermedad newcastle y uso del virus de la enfermedad newcastle en la preparacion de dichavacuna
ES2042718T3 (es) Procedimiento para la preparacion de una vacuna para proteger aves de corral contra septicemia producida por e. coli.
DK0709460T3 (da) Fjerkrævaccine imod coccidiosis
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
BR9706133A (pt) Mycoplasma synoviae atenuado vivo cultura microbiológica vacina para a proteção de aves domésticas processo para sua preparação e uso da cepa mycoplasma synoviae
BR9606725A (pt) Vacina para administração via mucosa eficaz para a proteção de frangos contra a queda de desempenho uso de um agente vivo atenuado de anemia de frango e processo para proteção de frangos contra a queda de desempenho
BR0108735A (pt) Proteção in ovo contra bronquite infecciosa
BR9602719A (pt) Virus da doença de Merek (MDV sorotipo 1) CEPA I-1585 de MDV vacina para a proteção de aves contra a doença de merek e processo para o desenvolvimento do MDV
ES2061165T3 (es) Vacuna para la proteccion de las aves de corral frente a la enfermedad de marek.
BR0003164A (pt) Mutante ndv, vacinas viva e inativada contra doença de newcastle em aves, uso de um mutante ndv, e, processo de proteção de aves contra nd
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
BR9305075A (pt) Antígeno para conferir imunidade protetora contra infecções helmínticas em humanos e animais,e processo de vacinação para aplicação na imunoprofilaxia de doenças helmintológicas de interesse veterinário e médico
AR007611A1 (es) Linea celular de pollo infectada con virus de la enfermedad de marek perdurable, metodo para producir la linea celular, vacuna para aves y lineacelular de herpesvirus de la enfermedad de marek
ES2055610T3 (es) Vacuna contra hrsv.
PL346195A1 (en) Chicken anaemia virus (cav) of weakened patogenicity, vaccine for protecting poultry against cav and method of obtaining cav of weakened pathogenicity

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MESMO APOS REITERADA ARGUMENTACAO ATRAVES DOS PARECERES TECNICOS, O QUADRO REIVINDICATORIO PERMANECE EM DESACORDO COM A LEI 9.279. ASSIM SENDO, DE ACORDO COM O ART. 37, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NO ARTIGO 10, INCISO IX DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27.07.2020